SAN DIEGO — Epcoritamab exhibited encouraging efficacy among heavily pretreated patients with advanced chronic lymphocytic leukemia, according to study results presented at ASH Annual Meeting and Exposition.
Mark Leiser is an editorial director at Healio, specializing in hematology/oncology and cellular therapy. With a focus on medicine and healthcare, he covers topics such as FDA developments, data analysis, and the impact of AI in the medical field. Leiser's work has been recognized in various prestigious competitions, highlighting his expertise and dedication to medical publishing.